Summary & Overview
HCPCS C9044: Injection, cemiplimab-rwlc, 1 mg
HCPCS Level II code C9044 designates the drug-specific billing unit for cemiplimab-rwlc, an immune checkpoint inhibitor administered by injection and reported per 1 mg. This code matters nationally as cemiplimab-rwlc is used in oncology and dermatology practices for approved indications, and unit-based drug codes drive pharmacy reimbursement, utilization monitoring, and drug-cost management across payers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how C9044 is used in billing drug administration services, the typical sites where the product is delivered, and what benchmarks and policy areas commonly affect its reimbursement—such as unitization, packaging rules, and payor-specific drug coverage policies. The publication also summarizes clinical context for cemiplimab-rwlc as a monoclonal antibody therapy and outlines where to look for payer policy updates and coding guidance.
This summary is intended to inform billing managers, revenue cycle staff, and policy analysts about the code’s role in claims processing, payer engagement, and clinical documentation needs. Data not available in the input indicates where readers should consult payer policy documents or pharmacy billing references for specifics on allowed units, modifier use, and diagnosis linkage.
Billing Code Overview
HCPCS Level II code C9044 represents an injection of cemiplimab-rwlc, billed per 1 mg unit. This code is used to report administration of the monoclonal antibody cemiplimab-rwlc when dosed and documented by milligram increments.
-
Service type: Drug administration (intravenous infusion or injectable monoclonal antibody therapy)
-
Typical site of service: Outpatient infusion center, hospital outpatient department, or physician office where parenteral oncology biologic therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with advanced or metastatic cutaneous squamous cell carcinoma or other FDA‑approved indication for cemiplimab‑rwlc who presents to an outpatient infusion center for administration of immunotherapy. The oncology clinic schedules the patient after staging and treatment planning; prior to infusion, a nurse verifies identity, reviews allergies, obtains baseline vital signs, confirms laboratory results (including complete blood count and liver function tests), and assesses for immune‑related contraindications. The pharmacy prepares the medication as C9044 (injection, cemiplimab‑rwlc, 1 mg) per weight‑based or fixed dosing protocols, performs sterility and label checks, and delivers the dose to the infusion suite. During the visit the patient is monitored for infusion reactions and immune‑related adverse events; documentation includes indication, dose administered in milligrams, lot number, infusion start and stop times, premedications if given, and patient tolerance. Typical follow‑up visits include interval assessment for response and toxicity and scheduling of subsequent C9044 administrations per the oncology regimen.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when an E/M visit is performed on the same day as administration and meets E/M documentation criteria |